Scottish Medicines Consortium



Ezetimibe (Ezetrol^o)

No. 61/03

Merck Sharpe & Dohme / Schering-Plough Ltd (UK) Summary of Recommendation

8 September 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

ADVICE

Recommended for restricted use within NHS Scotland

RECOMMENDATION

Ezetimibe may be considered in combination with a statin for patients who have failed to reach target cholesterol levels despite treatment with titrated/optimised statins alone. It may also be considered as monotherapy where statins are inappropriate or poorly tolerated.

Professor David H Lawson Chairman